Methylenetetrahydrofolate reductase C677T polymorphism and liver fibrosis progression in patients with recurrent hepatitis C

Pierluigi Toniutto, Carlo Fabris, Edmondo Falleti, Annarosa Cussigh, Elisabetta Fontanini, Davide Bitetto, Ezio Fornasiere, Rosalba Minisini, Tullia De Feo, Francesca Marangoni, Mario Pirisi

Research output: Contribution to journalArticle

Abstract

Background/Aims: Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism, being a putative steatogenic factor, may promote liver fibrosis progression in patients with chronic hepatitis C. This study aimed to verify the role of recipient MTHFR polymorphism in favouring graft fibrosis progression in patients with recurrent HCV after orthotopic liver transplantation (OLT). Methods: We studied 63 such patients, followed for >1 year. MTHFR allelic variants were determined by a polymerase chain reaction/restriction fragment length polymorphism method. Results: Recipients carrying the TT genotype had more frequently, 1-year post-OLT, homocysteine serum levels >23 μmol/L (P <0.05), serum triglycerides >180 mg/dL (P <0.02) and de novo diabetes mellitus (P 2 was performed by stratifying the recipients as follows: (a) patients with donor age ≤45 years, (b) patients with donor age >45 and C/* genotype, and (c) patients with donor age ≤45 years and TT genotype. A significant linear trend was observed, with increasing frequencies as follows: (a) 8/37, (b) 10/19 and (c) 6/7 (P = 0.0005). Conclusion: The MTHFR C677T polymorphism may play a role in influencing liver fibrosis progression in patients with recurrent hepatitis C, in conjunction with donor age, but not via steatosis promotion.

Original languageEnglish
Pages (from-to)257-263
Number of pages7
JournalLiver International
Volume28
Issue number2
DOIs
Publication statusPublished - Feb 2008

Keywords

  • Hepatitis C
  • Liver fibrosis
  • Liver transplantation
  • MTHFR gene

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Methylenetetrahydrofolate reductase C677T polymorphism and liver fibrosis progression in patients with recurrent hepatitis C'. Together they form a unique fingerprint.

Cite this